GH1 and hypogonadism: Female CP patients face a two-fold higher risk of metabolism-related cardiovascular mortality secondary to hypogonadism, when compared to the general population, which may be attributed to the insufficient attention to GH and gonadal hormone replacement therapy in adult CP patients (14, 48).